Staging Workup, Sentinel Node Biopsy, and Follow-up Tests for Melanoma: Update of Current Concepts

Archives of Dermatology

Volumn 140, Issue 1, 2004, Pages 107-113

  Johnson, Timothy M ^a,b   Bradford, Carol R ^b   Gruber, Stephen B ^b   Sondak, Vernon K ^a   Schwartz, Jennifer L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHATIC DRAINAGE; MELANOMA; MORBIDITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SYMPTOMATOLOGY;

HUMANS; LYMPH NODES; MELANOMA; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 0346499540     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.1.107     Document Type: Review

References (55)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin. 2003;53:5-26.
2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19:3635-3648.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
4. Sober AJ, Chuang TY, Duvic M, et al, for the Guidelines/Outcomes Committee. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001; 45:579-586.
5. Johnson TM, Chang A, Redman B, et al. Management of melanoma with a multidisciplinary melanoma clinic model. J Am Acad Dermatol. 2000;42:820-826.
6. Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520-529.
7. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients: monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151-157.
8. Mooney MM, Kulas M, McKinley B, Michalek AM, Kraybill WG. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol. 1998;5:54-63.
9. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703-1705.
10. Connell LE, Verheyden CN. The efficacy of laboratory studies in the detection of recurrent melanoma. Plast Reconstr Surg. 2003;111:502-503.
11. Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol. 1998;134:569-572.
12. Collins CD, Padley SP, Greenwell F, Phelan M. The efficacy of a single postero-anterior radiograph in the assessment of metastatic pulmonary melanoma. Br J Radiol. 1993;66:117-119.
13. Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol. 1997; 4:396-402.
14. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol. 1995;13:2104-2108.
15. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol. 1993;11:638-643.
16. Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M, Sertoli MR, Rosso R. Stage I-II melanoma: the value of metastatic work-up. Oncology. 1987;44:87-89.
17. Khansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg. 1989;124:847-849.
18. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma: a retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology. 1995;191:199-203.
19. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer. 1997;80: 1052-1064.
20. Evans RA, Bland KI, McMurtrey MJ, Ballantyne AJ. Radionuclide scans not indicated for clinical stage I melanoma. Surg Gynecol Obstet. 1980;150:532-534.
21. Au FC, Maier WP, Malmud LS, Goldman LI, Clark WH Jr. Preoperative nuclear scans in patients with melanoma. Cancer. 1984;53:2095-2097.
22. Blum A, Schlagenhauff B, Stroebel W, Breuninger H, Rassner G, Garbe C. Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. Cancer. 2000;88: 2534-2539.
23. Chao C, McMasters KM. Update on the use of sentinel node biopsy in patients with melanoma: who and how. Curr Opin Oncol. 2002;14:217-220.
24. Dessureault S, Soong SJ, Ross MI, et al, for the American Joint Committee on Cancer (AJCC) Melanoma Staging Committee. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001; 8:766-770.
25. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983.
26. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-2260.
27. Thompson JF, Uren RF. Lymphatic mapping and sentinel node biopsy for melanoma. Expert Rev Anticancer Ther. 2001;1:446-452.
28. Kelley MC, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol. 1998;14:283-290.
29. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Clin Oncol. 2003;21:520-529.
30. Eggermont AM. European approach to the treatment of malignant melanoma. Curr Opin Oncol. 2002;14:205-211.
31. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma: an analysis of related prognostic factors. Cancer. 1997;79:2345-2353.
32. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351:793-796.
33. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol. 2001;19: 2851-2855.
34. Brobeil A, Cruse CW, Messina JL, et al. Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am. 1999;8:435-445.
35. Leong WL, Ghazarian DM, McCready DR. Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity. J Surg Oncol. 2003;82:143-146.
36. Schmalbach CE, Nussenbaum B, Rees RS, Schwartz J, Johnson TM, Bradford CR. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2003;129:61-65.
37. Makar AP, Scheistroen M, van den Weyngaert D, Trope CG. Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy: review of literature. Int J Gynecol Cancer. 2001;11:255-262.
38. Esmaeli B. Sentinel node biopsy as a tool for accurate staging of eyelid and conjunctival malignancies. Curr Opin Ophthalmol. 2002;13:317-323.
39. Neville HL, Andrassy RJ, Lally KP, Corpron C, Ross MI. Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg. 2000;35:961-964.
40. McMasters KM, Chao C, Wong SL, et al, for the Sunbelt Melanoma Trial Group. Interval sentinel lymph nodes in melanoma. Arch Surg. 2002;137:543-547.
41. Uren RF, Howman-Giles R, Thompson JF, et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg. 2000;135:1168-1172.
42. Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. 1999;189:195-204.
43. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003;21: 1326-1331.
44. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR III, Leong SP. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998;134:983-987.
45. Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol. 2003;10:27-31.
46. Megahed M, Schon M, Selimovic D, Schon MP. Reliability of diagnosis of melanoma in situ. Lancet. 2002;359:1921-1922.
47. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002; 138:603-608.
48. Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol. 1998;39:422-427.
49. Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol. 2001; 19:2844-2850.
50. Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer. 2002;95:1562-1568.
51. Whited JD, Grichnik JM. The rational clinical examination:does this patient have a mole or a melanoma? JAMA. 1998;279:696-701.
52. Grob JJ, Bonerandi JJ. The "ugly duckling" sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998;134:103-104.
53. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536-540.
54. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1579.
55. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63:1602-1607.